Immunogen (IMGN) Misses Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- S&P Global explores potential separation of Capital IQ business
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Clear Street Starts Forgent Power Solutions (FPS) at Buy
RBC Capital Downgrades Immunogen Inc. (IMGN) to Sector Perform
May 2, 2016 10:52 AM EDTRBC Capital downgraded Immunogen Inc. (NASDAQ: IMGN) from Outperform to Sector Perform with a price target of $7.00 (from $18.00).
For an analyst ratings summary and ratings history on Immunogen Inc. click here. For more ratings news on Immunogen Inc. click here.
Shares of Immunogen Inc. closed at $6.85 yesterday.
... MoreImmunogen's (IMGN) Price Target Reduced to $5 at Morgan Stanley
May 2, 2016 9:49 AM EDTMorgan Stanley maintained an Underweight rating on Immunogen Inc. (NASDAQ: IMGN) and lowered its price target to $5.00 (from $9.00).
For an analyst ratings summary and ratings history on Immunogen Inc. click here. For more ratings news on Immunogen Inc. click here.
Shares of Immunogen Inc. closed at $6.85 yesterday.
... MoreUPDATE: RBC Capital Cuts Immunogen Inc. (IMGN) to 'Sector Perform' on Concerns About Lead Asset
April 29, 2016 2:28 PM EDT(Updated - April 29, 2016 2:44 PM EDT)
RBC Capital downgraded Immunogen Inc. (NASDAQ: IMGN) from Outperform to Sector Perform with a price target of $7.00 (from $18.00). Analyst Simos Simeonidis didn't like what he heard on the company's conference call regarding lead asset mirvetuximab soravtansine.
"We are downgrading IMGN to Sector Perform (from Outperform) on the news that lead asset mirvetuximab soravtansine produced a... More



